Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Participants with type 2 diabetes mellitus~* Substudy inclusion criteria:~  * Completion of the 6-month study period in main study (Visit 10)~ * Randomized and treated with insulin glargine new formulation during the 6-month treatment period (Baseline - month 6)~Exclusion criteria:~* Age less than (\<) 18 years~* HbA1c \<7.0% or greater than (\>) 10% at screening~* Diabetes other than type 2 diabetes mellitus~* Less than 1 year on basal plus mealtime insulin and self-monitoring of blood glucose~* Any contraindication to use of insulin glargine as defined in the national product label~* Participants using human regular insulin as mealtime insulin in the last 3 months before screening visit~* Use of an insulin pump in the last 6 months before screening visit~* Initiation of new glucose-lowering agents and/or weight loss drugs in the last 3 months before screening visit~* History or presence of significant diabetic retinopathy or macular edema likely to require laser or injectable drugs or surgical treatment during the study period~* Pregnant or breast-feeding women or women who intend to become pregnant during the study period~* Substudy exclusion criteria:~  * Participant not willing to use the adaptable injection intervals on at least two days per week~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HOE901-U300 (Type: EXPERIMENTAL): None
- Lantus (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).